12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Ethypharm, Gruenenthal sales and marketing update

Ethypharm granted Gruenenthal an exclusive license to commercialize Ethypharm's fentanyl sublingual tablets in selected EU countries to treat...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >